← Eichor
Condition: Ssc Systemic Sclerosis Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Ssc Systemic Sclerosis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

US Zamto-cel Autoimmune Diseases
Phase 1 · 1 location(s) · Miltenyi Biomedicine GmbH · NCT06708845Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis
NA · 5 location(s) · Primus Pharmaceuticals · NCT06256575A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
Phase 1 · 2 location(s) · Beijing GoBroad Hospital · NCT06980597Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
Phase 1/Phase 2 · 1 location(s) · Peking University Third Hospital · NCT06828042Home-Based Clinical Management of Cardiac Complications in Systemic Sclerosis
Phase N/A · 1 location(s) · Oslo University Hospital · NCT06865118CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07315087Patients Diagnosed With Scleroderma: Physical Performance and Functionality
Phase N/A · 1 location(s) · Hacettepe University · NCT07183072A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07104721Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.
Phase 1/Phase 2 · 1 location(s) · Beijing GoBroad Hospital · NCT06947473A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT06978647CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
Phase 1 · 1 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT07305116CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06941129A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Disease
Phase 1 · 28 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT07115745A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
Phase 2 · 76 location(s) · argenx · NCT06655155Patients Diagnosed With Scleroderma and Their Chewing and Swallowing Performance
Phase N/A · 1 location(s) · Hacettepe University · NCT07182981Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
Phase 2 · 2 location(s) · Johns Hopkins University · NCT04797286A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With
Phase 1 · 14 location(s) · Allogene Therapeutics · NCT07085104Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Relate
Phase 2 · 15 location(s) · aTyr Pharma, Inc. · NCT05892614Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
NA · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06614270Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Diseas
Phase N/A · 1 location(s) · Hospital Universitario Araba · NCT07249060Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed Wi
NA · 1 location(s) · Hacettepe University · NCT07292961Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis
Phase 2 · 6 location(s) · Topadur Pharma AG · NCT06954597TENS in Scleroderma
Phase 1 · 1 location(s) · University of Michigan · NCT06646913Multicenter Study on the Development of Pulmonary Arterial Hypertension Screening Models Based on Artificial Intelligenc
Phase N/A · 5 location(s) · Alejandro Cruz Utrilla · NCT07236970Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）
Phase 1 · 1 location(s) · Shenzhen MagicRNA Biotechnology Co., Ltd · NCT06801119A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Ass
Phase 3 · 10 location(s) · GlaxoSmithKline · NCT06716606A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, a
Phase 2 · 4 location(s) · Changchun GeneScience Pharmaceutical Co., Ltd. · NCT06189495MTS109 in Patients With Refractory Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · Shanghai Changzheng Hospital · NCT07526350The Clinical Study on the Treatment of SSc With UTAA91 Injection.
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07000682A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases
Phase 1 · 1 location(s) · Xencor, Inc. · NCT07284797
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.